Search PubMed⌕ Search

Biomedical subjects

M Umeda

Publications and source records attributed to M Umeda.

545 records · Page 31Linked to original sources
PubMedDate not supplied

Reproducibility of short echo time proton magnetic resonance spectroscopy using point-resolved spatially localized spectroscopy sequence in normal human brains.

The reproducibility of short echo time proton MR spectroscopy (1H-MRS) in normal human brains was examined. Thirteen healthy volunteers were studied, and each underwent three MRS examinations. Second and third measurements were done on the same day, about two months after the first measurement, and interday and intraday reproducibility were evaluated. MRS was performed with proton brain examination/single voxel (PROBE/SV) and point-resolved spatially localized spectroscopy (PRESS) (repetition time = 2000 ms, echo time = 30 ms). Five metabolite ratios were computed; N-acetyl-aspartate (NAA)/creatine (Cr), choline (Cho)/Cr, myo-inositol (mI)/Cr, NAA/(NAA + Cr + Cho), and NAA/Cho. Their normal range and reproducibility were measured. For each metabolite ratio, there was no significant difference between interday difference and intraday difference, suggesting that the interval of two months has minimal effect on MRS measurements. MRS may be utilized for the observation of central nervous system diseases.

Adult↗
PubMedDate not supplied

Effect of desferrioxamine infusion on red blood cell aluminum.

The authors investigated the effect of desferrioxamine (DFO) on red blood cell aluminum (RBC-AI) and the effect of DFO on anemia. To do this, serum AI (s-AI), RBC-AI, and blood hemoglobin (Hb) levels were measured periodically for 4 months after the administration of 1,000 mg of DFO (DFO infusion test) in 10 patients treated by hemodialysis (HD). The s-AI levels increased by 2 days after the administration of DFO and then decreased by day 7 to almost baseline levels. No significant changes occurred in the RBC-AI levels until 1 month postinfusion, at which time the levels decreased slowly for the following month. Hb levels increased at 1 month postinfusion, suggesting that the changes in RBC-AI were independent of the changes in s-AI. Removal of AI by DFO may improve the anemia that accompanies diseases in which AI accumulates. DFO did not seem to transfer AI into the RBC or to remove the AI that had accumulated in these cells.

Adult↗
PubMedDate not supplied

A phase II study of epirubicin in acute leukemia: a cooperative group study.

A new doxorubicin analogue, epirubicin (EPI), was evaluated in 41 patients with acute leukemia at 11 Japanese institutions participating in a phase II study between January 1983 and July 1985; during this period 35 patients were considered evaluable. There were 25 males and 10 females with a median age of 43 years (range, 19-71 years) and the median PS of 2 (range, 0-4). EPI was given to 25 patients who had previously been treated with intensive combination chemotherapy, of whom 22 had already received anthracyclines. Ten patients had not been treated previously. Two dose schedules were explored. The higher dose schedule (18 cases) consisted of the administration of 24 to 60 mg/m2 for 3 to 5 consecutive days, and the lower dose schedule (17 cases) consisted of 11 to 20 mg/m2 for 5 to 7 days. Remissions were obtained in 7 patients (20%), 2 of whom showed complete remission and 5 partial remission. The remission duration was 2, 2, 3, 5, 16, 16 and 29+ weeks, respectively. The expected myelosuppression was universal. Stomatitis occurred in 15 patients, of which 7 cases were severe. This stomatitis occurred frequently in the higher dose schedule, and was thought to be a dose-limiting factor. In others, alopecia, G.I. symptoms, and diarrhoea (4 patients) were seen. These results from a cooperative group study indicated that EPI was an effective drug for the treatment of acute leukemia.

Acute Disease↗